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Abstract
Objective: To assess the sensitivity, the number needed to screen (NNS) and the positive predictive value
(PPV) of cervical cytology for the diagnosis of cancer by age in a screening population.
Methods: A retrospective cohort of women with invasive cervical cancer nested within a census of cervical
cytology. All (c. 8 million) women aged 20–64 years with cervical cytology (excluding tests after an earlier
abnormality). From April 2007 to March 2010, 3372 women had cervical cancer diagnosed within 12 months
of such cytology in England. The sensitivity of cervical cytology to cancer, NNS to detect one cancer and pre-
dictive values of cytology were calculated for various ’referral‘ thresholds. These were calculated for ages 20–
24, 25–34, 35–49 and 50–64 years.
Results: The sensitivity of at least moderate dyskaryosis [equivalent to a high-grade squamous intraepithelial
lesion (HSIL) or worse] for cancer of 89.4% [95% confidence interval (CI) 88.3–90.4%] in women offered
screening was independent of age. At all ages, women with borderline-early recall or mild dyskaryosis on
cytology (equivalent to ASC-US and LSIL, respectively, in the Bethesda system) had a similar risk of cervical
cancer to the risk in all women tested. The PPV of severe dyskaryosis/?invasive and ?glandular neoplasia
cytology (equivalent to squamous cell carcinoma and adenocarcinoma/adenocarcinoma in situ, respectively, in
the Bethesda System) were 34% and 12%, respectively; the PPV of severe dyskaryosis (HSIL: severe dysplasia)
was 4%. The NNS was lowest when the incidence of cervical cancer was highest, at ages 25–39 years, but the
proportion of those with abnormal cytology who have cancer was also lowest in younger women.
Conclusions: The PPV of at least severe dyskaryosis (HSIL: severe dysplasia) for cancer was 4–10% of women
aged 25–64 years, justifying a 2-week referral to colposcopy and demonstrating the importance of failsafe moni-
toring for such patients. The sensitivity of cytology for cervical cancer was excellent across all age groups.
Keywords: cervical cancer, cervical cytology, predictive value of tests, sensitivity, specificity, pap test
Introduction
Cervical screening aims to prevent cervical cancer
through the diagnosis and treatment of premalignant
cervical lesions. Although screening can lead to the
early diagnosis of invasive cervical cancer, which is
not its primary goal, and the value of cytology to
detect cancer (rather than pre-cancerous lesions) has
not been studied.
This paper considers the results of a census of cer-
vical cytology; we show the distribution of cytology
results, by age, in the general (screening) population
and women with cervical cancer. We explore the
sensitivity and positive predictive value (PPV) of cer-
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vical cytology at different thresholds for the detec-
tion of invasive cervical cancer in the general
screening population, as well as the number of
women needed to be screened (NNS) to detect one
case of invasive cervical cancer.
During the study period (2006–2010) the tech-
nology used for screening in England changed.
Liquid-based cytology (LBC) was introduced
between 2003 and 2008 and will have resulted in
cytology slides taken during the study period
reported in a combination of conventional cytology
and one of the two systems of LBC. In addition,
six large cytology laboratories in England were
using HPV testing to triage borderline and mild
dyskaryosis(equivalent to ASC-US and LSIL,
respectively, in the Bethesda system) during most
of this period.
Materials and methods
For the results of cytology in women with cervical
cancer, we used data from the National Audit of
Invasive Cervical Cancers in England.1–3 We studied
a retrospective cohort of women who had had cervi-
cal cytology taken in the 12 months prior to diagno-
sis, between April 2007 and March 2010. All
cervical cytology was read using the British Society
for Clinical Cytology (BSCC) terminology in labora-
tories subject to accreditation and quality assurance.
Data on their screening histories were abstracted
from cervical cytology records held on the Exeter
Call/Recall System. For results in the general popu-
lation we used an extract from the Exeter database
(taken in October/November 2010) including annual
attendances to the screening programme from April
2007 to March 2010.4 This resulted in a census of
cytology results. The information in this extract
included the women’s age, test result and category
of screening invitation (for example routine recall,
early recall after an abnormality or surveillance after
treatment). In both women with cancer and the
general population, we excluded cytology that was
taken because of an earlier abnormal result. Note
that by considering cytology in a 3-year window
and excluding repeat tests, few women will have
more than one test in this study. For women with
cervical cancer, we define the ‘index test’ as the first
non-recall (i.e. not a follow-up test) test result
within 12 months of diagnosis. Twelve months was
chosen to allow for diagnosis after early (6-month)
recall triggered by borderline or mild dyskaryotic
cytology (equivalent to ASC-US and LSIL, respec-
tively, in the Bethesda system) while ensuring that
the cancer was already present at the time of cytol-
ogy. Sensitivity analyses taking the index test as the
first within 9 and 18 months of diagnosis were also
carried out.
The BSCC terminology can be compared broadly
with the Bethesda System (TBS) as follows5: Border-
line changes (early recall) includes atypical squa-
mous cells (ASC) and atypical glandular cells (AGC).
Borderline, high-grade dyskaryosis not excluded,
equivalent to ASC, cannot exclude a high-grade
squamous intraepithelial lesion (ASC-H). The term
dyskaryosis equates to a squamous intraepithelial
lesion (SIL); mild dyskaryosis corresponds to a low-
grade squamous intraepithelial lesion (LSIL); high-
grade dyskaryosis (equating to HSIL) is defined as
moderate or severe dyskaryosis. Separate categories
exist for severe dyskaryosis/?invasive and ?glandular
neoplasia for squamous cell carcinoma and cervical
glandular intraepithelial neoplasia (CGIN) ⁄ adeno-
carcinoma, respectively.
Borderline cytology results were divided into two
groups reflecting the associated differing risk of dis-
ease. ‘Borderline-high risk’ comprises tests for
which immediate referral to colposcopy is recom-
mended (because the high-grade disease could not
be ruled out). ‘Borderline low-risk’ comprises tests
for which a repeat test at 6 months is recom-
mended.6 In England, although text reports distin-
guish borderline changes in which high-grade
cannot be excluded, result codes on national
records do not record subtypes of borderline.
Because we did not have access to cytology reports,
we used cytology test action codes of ‘suspend’ (i.e.
referral to colposcopy) and ‘early-recall’ (i.e. repeat
cytology in 6 months) to classify women as ‘border-
line-high risk’ and ‘borderline low-risk’, respec-
tively. Borderline samples with a positive HPV
triage test and those with changes in endocervical
cells are included in the borderline-high risk group
as these samples would have triggered an immedi-
ate referral to colposcopy. Cytology test action codes
were available for all women with cancer and a
random sample (i.e. controls from the National
Audit) of the general population. The proportion of
controls classified as ‘borderline-high risk’ was
applied to the census of cytology results to estimate
the proportion of the general population.
We estimated the number needed to screen
(NNS), the positive predictive value (PPV) and sen-
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sitivity for cervical cancer according to three differ-
ent groupings of cytology test results. This allowed
us to assess which women would be likely to
benefit from a 2-week referral to colposcopy for
further investigation. These were defined as fol-
lows: Level 1 includes severe dyskaryosis or
worse cytology results; Level 2 includes borderline-
high risk, moderate dyskaryosis or worse cytology
results; and Level 3 includes all cytological tests
that resulted in a referral to colposcopy based on
the screening programme protocols prior to
diagnosis. Box 1 details the BSCC and Bethesda
terminology included in each referral threshold
Level.
Statistical analysis
Sensitivities were calculated as the proportion of
women with cancer who had a positive test when
considering each cytology result. Specificities were
Box 1. Referral threshold Levels* for colposcopy with their respective BSCC and Bethesda terminology
Level 1 Level 2 Level 3
BSCC Bethesda BSCC Bethesda BSCC Bethesda
Severe
dyskaryosis
HSIL Borderline, high-grade
dyskaryosis not excluded
ASC-H Third consecutive
inadequate test
Unsatisfactory for
evaluation
Severe
dyskaryosis
?invasive
Squamous
cell carcinoma
Borderline change in
endocervical cells
Atypical
endocervical,
endometrial
or glandular.
First or second mild;
second or third
consecutive
borderline
LSIL, Atypical
squamous cells
of undetermined
significance
(ASC-US).
?Glandular
neoplasia
AGC, favour
neoplastic/AIS
Adenocarcinoma:
endocervical
endometrial
extrauterine
not otherwise
specified (NOS)
High-grade dyskaryosis,
moderate or severe
HSIL Borderline,
high-grade
dyskaryosis
not excluded
ASC-H and AGC
Severe dyskaryosis
?invasive
Squamous cell
carcinoma
High-grade
dyskaryosis,
moderate or severe
HSIL
?Glandular neoplasia AGC, favour
neoplastic/AIS
Severe dyskaryosis
?invasive
Squamous cell
carcinoma
Adenocarcinoma:
endocervical
endometrial
extrauterine
not otherwise
specified (NOS)
?Glandular
neoplasia
AGC, favour
neoplastic/AIS
Adenocarcinoma:
endocervical
endometrial
extrauterine
not otherwise
specified (NOS)
*Note: threshold levels are not mutually exclusive. BSCC, British Society for Clinical Cytology; LSIL, Low-
grade Squamous Intraepithelial Lesion; HSIL, High-grade Squamous Intraepithelial Lesion; AIS, adenocarci-
noma in situ; ASC-H, atypical cells of undetermined significance, cannot exclude a high-grade squamous intra-
epithelial lesion; ASC-US, atypical cells of undetermined significance; AGC, atypical glandular cells.
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calculated as the proportion of women without can-
cer who had a test result less severe than the rele-
vant cut-off. The PPVs were calculated by dividing
the number of cancers diagnosed with a given index
test result by the number of cytology tests (in the
general population during the same period) with
that test result. It was not possible to calculate the
PPV for Level 3 cytology as the action code of each
cytology test was not available in our extract of the
Exeter database. The NNS is the total number of
cytology tests divided by the total number of cancers
diagnosed after cytology with that result or worse.
To calculate the 95% confidence intervals (CIs) for
the NNS, a 95% CI for the PPV was calculated
assuming the number of cancers diagnosed from the
number of cytology tests carried out has a binomial
distribution, and the inverse was taken.7 Confidence
intervals for borderline-low risk and borderline-
high-risk took into account (by simulation) that the
number of cytology tests in each of these categories
in the general population was estimated. Analyses
were carried out in STATA 12 (StataCorp., College
Station, TX, USA).
Results
Cytology results
There were 3372 women diagnosed with cervical
cancer, who had a routine (i.e. one not following a
previous action code of early recall or suspend)
cytology test within 12 months of diagnosis,
between 1st April 2007 and 31st March 2010. Over
the same period, there were 8 214 754 routine
cytology tests in England (Figure 1). The majority of
screening age cytology tests were negative (92.2%),
1.3% were Level 2 (moderate dyskaryosis or worse
including borderline-high risk), and 0.6% were
Level 1 (severe dyskaryosis or worse) (Table 1). The
percentage that was negative increased with age
(Supplementary Table S1), from 82.0% in women
aged 20–24 years to 94.9% in women aged 50–
64 years. The proportion of tests that were inade-
quate remained consistent across age groups, ranging
from 2.6% to 3.1% and remained similar over the
study period. The percentage that were Level 2 was
higher in young women (20–24 years: 3.7%, 25–
34 years: 2.4%) than the older age groups (35–
49 years: 0.9%, 50–64 years: 0.4%) (Table 2).
NNS, sensitivity and predictive values
The NNS to identify one cancer in women aged 20–
64 years with Level 2 cytology was 2726 (95% CI:
2630–2826) and the NNS was lowest for women
aged 25–39 (1913, 95% CI: 1810, 2024). Trends in
the NNS with age are shown in Figure 2a. The NNS
is lowest when the incidence of cervical cancer is
highest, at ages 25–39 years.
In 78% of women aged 20–64 years with cervi-
cal cancer with at least one test within 12 months
of diagnosis, the first such test was Level 1 and
89% were Level 2. The sensitivity of cytology to
cervical cancer was largely independent of age
(Figure 2b).
Overall, the PPV for cervical cancer of a severe
dyskaryosis/?invasive report was 33.5% (95% CI:
31.3–35.8%), the PPV of a report of ?glandular neo-
plasia was 12.4% (95% CI: 11.4–13.5%) and 3.6%
(95% CI: 3.4–3.8%) for a report of severe dyskaryo-
sis (Table 1). The PPV of moderate dyskaryosis was
much less: 0.66% (95% CI: 0.57–0.75%) (i.e. 1 in
153 women with moderate dyskaryosis had cervical
cancer), which was similar to the PPV of a border-
line-high risk (0.61%, 95% CI: 0.52–0.71%). The
overall PPV of all Level 2 cytology was 2.77% (95%
11,293,906 cytology tests taken 
April 2007 – March 2010
122,271 tests not 
aged 20-64
18 tests have no 
result recorded
8,214,754 cytology tests included 
in the analysis
7,054 cancers diagnosed April 
2007-March 2011 aged 20-65
2,165 no cytology 
April 2007 – March 
2010
1503 no routine 
cytology within 12 
months of diagnosis
14 not aged 20-64 
at index cytology
Census of cytology tests Cervical cancers
2,956,863 tests 
following an 
abnormal test result
3,372 cancers included in the 
analysis
Figure 1. Inclusions and exclusions
from the study
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CI: 2.67–2.87%), whereas the PPV of Level 1 cytol-
ogy was 5.34% (95% CI: 5.14–5.54%) (Table 1).
The PPV of Levels 1 and 2 cytology increased with
age (Table 2). The PPV of inadequate tests remained
below the overall PPV for all women having a cytol-
ogy test across all ages (0.03% for women aged 25–
34 years, 35–49 years and 50–64 years). Trends in
PPV of cytology to cancer by age are shown in Fig-
ure 2c.
The PPVs of mild dyskaryosis (0.07%, 95% CI:
0.05–0.09%) and of borderline-low risk (0.06%,
95% CI: 0.05–0.07%) were similar to the prevalence
of cancer in all screened women (0.041%, 95% CI:
0.040–0.042%). In other words, the chance of the
cancer being diagnosed in the next year in a woman
with mild dyskaryosis is only slightly higher than in
a randomly selected woman attending screening (1
in 2436).
Women’s first screen
When data for young women were split according
to whether it was the woman’s first screen or sub-
sequent screen, the proportion of Level 2 results
was slightly higher for first screens (age 20–
24 years: first screen 4.0%, subsequent screens
3.6%; age 25–29: first screen 3.2%, subsequent
screens 2.7%). However, the PPV of a Level 1
cytology result was substantially higher for first
screens than subsequent screens, particularly at age
Table 1. Result of the first routine cytology test in the last 12 months in women aged 20–64 years, with cervical cancer
(‘Cancers’) and in the general population (‘Cytology tests’) and the positive predictive value (PPV) of the test result to cervi-
cal cancer
Cytology test result*
Aged 20–64
Cancers
% cancers
diagnosed
with test result
or worse Cytology tests % of all tests PPV
Negative 106 100 7 570 265 92.2 0.00%
Inadequate 58 97 221 956 2.7 0.03%
Borderline – low risk 118 95 203 322 2.5 0.06%
Mild dyskaryosis 76 92 110 333 1.3 0.07%
Borderline – high risk 164 89 26 672 0.3 0.61%
Moderate dyskaryosis 215 85 32 823 0.4 0.66%
Severe dyskaryosis 1589 78 43 930 0.5 3.62%
?Glandular neoplasia 459 31 3701 0.0 12.40%
?Invasive squamous carcinoma 587 17 1752 0.0 33.50%
Total 3372 8 214 754 0.04%
Level 1 2635 78 49 383 0.6 5.34%
Additional value of moderate
dyskaryosis and borderline-high
risk cytology
379 11 59 495 0.7 0.64%
*First routine cytology test in the last 12 months.
Table 2. Positive predictive value (PPV) of high grade
(Level 2) and severe dyskaryosis or worse (Level 1) cyto-
logy to cervical cancer by age at diagnosis
Age
group
Tests and cancers between April 07/March 10
Cancers
with test
result
% cancers
diagnosed
with
test result
Cytology
tests with
result
% of all
Cytology
tests
PPV
(%)
Level 2*
20–24 97 87 9599 3.7 1.0
25–34 1246 91 57 006 2.4 2.2
35–49 1293 89 34 825 0.9 3.7
50–64 378 86 7447 0.4 5.1
Level 1*
20–24 76 68 3785 1.5 2.0
25–34 1069 78 27 484 1.2 3.9
35–49 1160 80 14 936 0.4 7.8
50–64 330 75 3178 0.2 10.4
*First routine cytology test in the last 12 months.
© 2015 The Authors Cytopathology Published by John Wiley & Sons Ltd.
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20–24 years [first screen 4.51% (95% CI: 3.45–
5.78%), subsequent screens 0.69% (95% CI: 0.40–
1.10%)] (Table 3). This reflects the fact that preva-
lent occult cancers are most likely detected on the
first screen.
Results by stage at diagnosis
FIGO (International Federation of Gynaecologists
and Obstetricians) stage was recorded for 91.6% of
cancers diagnosed aged 20–64 years. Over half of
those without cytology in the 12 months prior to
diagnosis had stage 2+ (57.5%) compared to only
11.0% of women with cytology in the 12 months
prior to diagnosis (Table 4).
The results were very similar when cytology
within 9 or 18 months of diagnosis was considered
in place of 12 months (Supplementary Table S2).
Discussion
We have shown that in a screening population,
regardless of age, the predictive value of cytology for
cervical cancer is extremely high for reports of
severe dyskaryosis/?invasive carcinoma (34%) and ?
glandular neoplasia (12%), and high for reports of
severe dyskaryosis (3.6%). Collectively these three
groups account for a high proportion (78%) of inva-
sive cervical cancers, and thereby confirm that the
current guidelines for a 2-week referral to colpos-
copy for severe dyskaryosis or worse cytology results
are appropriate. Additionally, our results demon-
strate the need for failsafe monitoring for women
with severe dyskaryosis or worse cytology.
The PPV of severe dyskaryosis or worse (Level 1)
cytology was substantially higher on the first cervical
screening test in young women than among those
who had been screened previously, reflecting the
large number of prevalent cancers diagnosed at first
screen, although it is important to note that in Eng-
land 72% of women aged 20–29 years diagnosed
with cervical cancer on their first cytology test had
stage 1A cancer.8 These results explain why the
number needed to screen is lower and the PPV of
cytology to cancer is higher among women under
the age of 35 years than among older women. The
sensitivity of cytology for cervical cancer is excellent;
in fact it is much better than the reported sensitivity
for CIN3 or worse.9 The sensitivity of cytology to
cancer was similar across all age groups.
Our results show that the risk of cancer in women
aged 20–64 years with borderline low-risk or mild
dyskaryosis (ASCUS/LSIL) was similar (PPV of bor-
derline-low risk changes or mild dyskaryosis 0.06%
and 0.07%, respectively) to that in all women tested
(regardless of the result, 0.04%). In contrast, the
PPVs of borderline-high risk (0.61%) and moderate
dyskaryosis (0.66%) were 15 times higher than the
overall risk among screened women.
When interpreting these findings it is important to
bear in mind that results refer to the use of cervical
cytology for the early diagnosis of cancer, and not
the standard use of cytology (i.e. screening for the
detection of precursor disease). As such, the NNS
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Figure 2. Number needed to screen, sensitivity and positive predictive value of cytology for cancer, by age group in three
different Levels of cytology cut off. Level 1: severe dyskaryosis or worse; Level 2 borderline-high-risk or worse; and Level 3
referred to cytology as per screening programme protocols.
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will be much higher and predictive values in this
paper much lower than those obtained in a screen-
ing context.
The main strength of this study is in the use of
cytology results for the entire population of England
together with the linked screening histories for
Table 3. Predictive value of cytology to cervical cancer by age at diagnosis
Cytology test
result*
Tests and cancers between April 07/March 10 Tests and cancers between April 07/March 10
Cancers
% cancers
diagnosed
with test
result or
worse
Cytology
tests
% of
all tests PPV Cancers
% cancers
diagnosed
with test
result or
worse
Cytology
tests
% of
all
tests PPV
Age 20–24 – first screen Age 20–24 – subsequent screen
Negative 0 100 63 167 83.2 0.00% 0 100 148 763 81.5 0.00%
Inadequate 0 100 2029 2.7 0.00% 0 100 5480 3.0 0.00%
Borderline –
low risk/mild
dyskaryosis
7 100 7694 10.1 0.09% 7 100 21 693 11.9 0.03%
Borderline –
high risk/
moderate
dyskaryosis
15 91 1698 2.2 0.88% 6 77 4116 2.3 0.15%
Severe
dyskaryosis
or worse
59 73 1307 1.7 4.51% 17 57 2478 1.4 0.69%
Total 81 75 895 0.107% 30 182 530 0.016%
Age 25–29 – first screen Age 25–29 – subsequent screen
Negative 4 100 365 199 86.4 0.00% 13 100 743 270 88.0 0.00%
Inadequate 2 99 10 800 2.6 0.02% 5 97 21 423 2.5 0.02%
Borderline –
low risk/mild
dyskaryosis
10 98 33 370 7.9 0.03% 30 96 56 991 6.7 0.05%
Borderline –
high risk/
moderate
dyskaryosis
28 94 7040 1.7 0.40% 65 89 12 071 1.4 0.54%
Severe
dyskaryosis
or worse
226 84 6330 1.5 3.57% 310 73 10 674 1.3 2.90%
Total 270 422 739 0.064% 423 844 429 0.050%
Age 30–34 – first screen Age 30–34 – subsequent screen
Negative 2 100 100 522 89.2 0.00% 11 100 915 341 91.2 0.00%
Inadequate 5 98 3417 3.0 0.15% 4 98 26 843 2.7 0.01%
Borderline –
low risk/mild
dyskaryosis
3 94 6200 5.5 0.05% 31 97 43 336 4.3 0.07%
Borderline –
high risk/
moderate
dyskaryosis
14 92 1249 1.1 1.12% 70 92 9163 0.9 0.76%
Severe
dyskaryosis
or worse
100 81 1308 1.2 7.65% 433 79 9172 0.9 4.72%
Total 124 112 696 0.110% 549 1 003 855 0.055%
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women diagnosed with cervical cancer. Thus, it has
wide-ranging validity and is essentially unbiased.
The number of borderline cytology tests that were
high risk in the screening population had to be esti-
mated from the audit dataset. However, as a result
of the introduction of HPV triage in England, the
new BSCC terminology guidelines10 no longer
include details on whether or not high-grade disease
can be excluded from borderline results, relying
instead on the HPV test result. Further, the introduc-
tion of LBC testing in England resulted in vigorous
training for laboratory and primary care staff just
prior to and during the study period, which may
have affected the PPV of cytology.
Despite the fact that vaginal cytology was first
described as a method of detecting cervical cancer11,
we are not aware of any studies showing the PPV of
modern cervical cytology to cancer. Results pre-
sented here demonstrate the usefulness of cytology
with a threshold of borderline-high risk or worse
(Level 2) for the diagnosis of cervical cancer, regard-
less of age. In fact, these cytology results were
observed in 89% of cancers.
There has been concern that cytology in the pres-
ence of invasive cancer is unreliable because the
cytology may be inadequate (or even negative). In
this study, we found no evidence (in any age group)
to suggest this, and additionally show that the pro-
portion of cytology tests that are inadequate in the
presence of cancer remains low across all age groups.
As some false-negative cytology does occur, it
remains important that GPs follow-up women with
gynaecological symptoms of possible cervical cancer,
and that they make a specialist referral if symptoms
persist or worsen.
A substantial benefit of cervical screening comes
from early diagnosis of occult cancers. The NNS to
detect one cancer using cervical cytology (2700 per
cancer) is considerably higher than the NNS to diag-
nose one colorectal cancer using faecal occult blood
tests (516 per cancer12). However, the incidence of
cervical cancer has been reduced by 46% since the
introduction of the national screening programme in
England in 1988, and it is difficult to estimate what
the incidence would be in the absence of screening.
This study reports cytology read using BSCC ter-
minology in laboratories subject to accreditation and
quality assurance, and the conclusions may not gen-
eralize to other systems for reporting cytology or to
countries with less quality assurance.
Conclusion
The PPV of severe dyskaryosis or worse cytology for
cervical cancer is 4–10% in women aged 25–64 years,
clearly justifying a 2-week referral to colposcopy and
emphasizing the importance of failsafe monitoring for
such patients. The sensitivity of cytology for cervical
cancer is excellent across all age groups.
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final version. P.D.S. affirms that the manuscript is
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Ethical approval
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vice evaluation that does not require research ethics
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